N/A N=36 Parent/Nurse Controlled Analgesia in the Neonatal Intensive Care Unit
Abdominal Surgery · Thoracic Surgery
Primary: Morphine Consumption — 0.014; 0.036 mg/kg/hr
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=15 Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
HCV Infection
Primary: Pharmacokinetic (PK) Parameter: AUCtau of Norelgestromin — 13757.4; 14690.4 hours*picogram/milliliter (h*pg/mL)
Phase 3 N=91 Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
Neovascular Age Related Macular Degeneration
Primary: Multifocal Electroretinography N1-P1 Amplitude — 3.6; 5.3; 4.9; 4.0 nV/deg^2
Phase 2 N=26 Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia
Primary: Very Good Partial Response Rate (VGPR) for IDR — 5 Participants
Phase 2 N=12 Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
Severe Sepsis · Septic Shock
Primary: Evaluate the Safety Profile of Pioglitazone in Patients With Severe Sepsis and Septic Shock as the Number of Hypoglycemic Events — 0; 0 events — p=1.0
N/A N=12 Brain Stimulation and Cognitive Training
Bipolar Disorder · Schizo Affective Disorder · Schizophrenia
Primary: Participant Retention in Combination Treatment — 4; 5 Participants
Phase 2 N=162 Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
Chronic Hepatitis B
Primary: Change From Baseline in Serum Hepatitis B Surface Antigen (HBsAg) Level at Week 24 — -0.011; 0.033; -0.018; -0.035 log10 IU/mL — p=0.590
Phase 4 N=107 Cost- Effectiveness and Quality of Life Assessment in Mood Disorder
Bipolar Disorder
Primary: Number of Participants With Response to Treatment" — 31; 28; 27 Participants
Phase 4 N=204 Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections
Acute Respiratory Viral Infections
Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms. — 4.1; 4.5 days — p=0.032
Phase 2 N=18 Walnuts to Achieve Lasting NUTrition to Prevent Diabetes
PreDiabetes · Overweight and Obesity
Primary: Number of Participants Recruited and Retained — 8; 9 Participants
N/A N=34 Investigation of the Safety and Efficacy of Pocket-X Gel
Periodontal Pocket
Primary: Change in Periodontal Pockets Probing Depth — 6.97; 6.81; 7.67; 7.72 mm
Phase 2 N=90 Clinical Trial of Integrated Treatment for Pain and Opioid Dependence
Opiate Dependence · Chronic Pain
Primary: Pain Intensity — 5.43; 5.92; 5.28; 4.75 units on a scale
Phase 2 N=272 A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs) — 215; 31; 32; 16 Participants
Phase 4 N=78 Single Shot Liposomal Bupivicaine in Rotator Cuff Surgery
Rotator Cuff Tear · Pain, Postoperative
Primary: Patient Reported Postoperative Pain: VAS — 3.1; 3.5; 2.4; 3.3 units on a scale
Phase 2 N=112 Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Chronic Myelogenous Leukemia
Primary: Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months — 74 Participants